Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prevention of the cryptic epitope SLAYGLR within osteopontin does not influence susceptibility to Candida albicans infection.

Literature DB >> 15980398

Prevention of the cryptic epitope SLAYGLR within osteopontin does not influence susceptibility to Candida albicans infection.

Ikuko Sato¹, Nobuchika Yamamoto, Harumi Yamazaki, Seiji Hashimoto, Motohiro Hino, Fumihiko Sakai, Akihiko Fujie.

Abstract

The effect of an antiosteopontin antibody (M5 Ab) reacting with the SLAYGLR sequence within osteopontin on the host susceptibility to infection was investigated in a murine model of disseminated candidiasis. The treatment with anti-tumor necrosis factor alpha antibody enhanced fungal infection, while the treatment with M5 Ab did not affect the infection.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 2005 PMID： 15980398 PMCID： PMC1168664 DOI： 10.1128/AAC.49.7.3053-3055.2005

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

13 in total

1. Peptidomimetic antagonists of alphavbeta3 inhibit bone resorption by inhibiting osteoclast bone resorptive activity, not osteoclast adhesion to bone.

Authors: C P Carron; D M Meyer; V W Engleman; J G Rico; P G Ruminski; R L Ornberg; W F Westlin; G A Nickols
Journal: J Endocrinol Date: 2000-06 Impact factor: 4.286

2. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin.

Authors: H Ihara; D T Denhardt; K Furuya; T Yamashita; Y Muguruma; K Tsuji; K A Hruska; K Higashio; S Enomoto; A Nifuji; S R Rittling; M Noda
Journal: J Biol Chem Date: 2001-01-22 Impact factor: 5.157

3. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity.

Authors: S Ashkar; G F Weber; V Panoutsakopoulou; M E Sanchirico; M Jansson; S Zawaideh; S R Rittling; D T Denhardt; M J Glimcher; H Cantor
Journal: Science Date: 2000-02-04 Impact factor: 47.728

4. Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis.

Authors: F Ikeda; Y Wakai; S Matsumoto; K Maki; E Watabe; S Tawara; T Goto; Y Watanabe; F Matsumoto; S Kuwahara
Journal: Antimicrob Agents Chemother Date: 2000-03 Impact factor: 5.191

5. Osteopontin expression correlates with clinical outcome in patients with mycobacterial infection.

Authors: G J Nau; G L Chupp; J F Emile; E Jouanguy; J S Berman; J L Casanova; R A Young
Journal: Am J Pathol Date: 2000-07 Impact factor: 4.307

6. Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin.

Authors: G J Nau; L Liaw; G L Chupp; J S Berman; B L Hogan; R A Young
Journal: Infect Immun Date: 1999-08 Impact factor: 3.441

7. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms.

Authors: S Kon; M Maeda; T Segawa; Y Hagiwara; Y Horikoshi; S Chikuma; K Tanaka; M M Rashid; M Inobe; A F Chambers; T Uede
Journal: J Cell Biochem Date: 2000-04 Impact factor: 4.429

Review 8. Tumor necrosis factor-alpha blockade: a novel therapy for rheumatic disease.

Authors: Joseph C Shanahan; William St Clair
Journal: Clin Immunol Date: 2002-06 Impact factor: 3.969

9. High plasma osteopontin level and its relationship with interleukin-12-mediated type 1 T helper cell response in tuberculosis.

Authors: Yoshinobu Koguchi; Kazuyoshi Kawakami; Kaori Uezu; Kiyoyasu Fukushima; Sigeyuki Kon; Masahiro Maeda; Atsushi Nakamoto; Isoko Owan; Mutsuo Kuba; Norifumi Kudeken; Masato Azuma; Satomi Yara; Takashi Shinzato; Futoshi Higa; Masao Tateyama; Jun-Ichi Kadota; Hiroshi Mukae; Shigeru Kohno; Toshimitsu Uede; Atsushi Saito
Journal: Am J Respir Crit Care Med Date: 2003-02-05 Impact factor: 21.405